Coherus Biosciences | CHRS - Debt


Coherus Biosciences reported $294.92M in Debt for its fiscal quarter ending in March of 2025.





Debt Change Date
AbbVie USD 70.82B 2.04B Jun/2026
Acadia Pharmaceuticals USD 73.85M 23.06M Jun/2026
Akebia Therapeutics USD 46.51M 7.82M Mar/2025
ALKERMES USD 1.57B 10.58M Sep/2026
Alnylam Pharmaceuticals USD 2.48B 1.21B Sep/2026
Amarin USD 0 0 Mar/2025
Amgen USD 57.3B 19M Jun/2026
Baxter International USD 9.67B 20M Jun/2026
Biogen USD 7.69B 398.3M Sep/2026
BioMarin Pharmaceutical USD 4.19B 11.99M Sep/2026
Bristol-Myers Squibb USD 42.88B 2.18B Sep/2026
Coherus Biosciences USD 294.92M 1.25M Mar/2025
Eli Lilly USD 54.91B 11.54B Jun/2026
Fujifilm JPY 1.03T 104.2B Mar/2026
Gilead Sciences USD 26.25B 4.07B Jun/2026
Ironwood Pharmaceuticals USD 583.99M 14.83M Dec/2024
Merck USD 53.91B 4.79B Jun/2026
Myriad Genetics USD 59.3M 19.7M Mar/2025
Pacira USD 293.59M 69.53M Sep/2026
Perrigo USD 3.29B 337.7M Jun/2026
Pfizer USD 62.67B 523M Sep/2026
PTC Therapeutics USD 2.84B 2.15B Sep/2026
Regeneron Pharmaceuticals USD 2.71B 400K Jun/2026
Sarepta Therapeutics USD 857.36M 188.48M Sep/2026
Teva Pharmaceutical Industries USD 16.98B 110M Sep/2026
Vertex Pharmaceuticals USD 6.48B 4.5B Sep/2026
Xencor USD 170.11M 5.06M Jun/2026
Zoetis USD 9.24B 0 Jun/2026